Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Massachusetts Healthcare Journal.
Press releases published on June 20, 2025
Sandra West ALS Foundation to Award Four Scholarships, Honoring Remarkable Students with Parents Affected by ALS
EIN Presswire
·
June 20, 2025
Empowering students impacted by ALS, the Sandra West ALS Foundation proudly announces its 2025 scholarship recipients for courage, resilience, and promise. BOSTON, MA, UNITED STATES, June 20, 2025 /EINPresswire.com/ -- The Sandra West ALS Foundation, …
Epiphany Wellness Sheds Light on Kleptomania: Understanding, Treating, and Overcoming a Silent Struggle
EIN Presswire
·
June 20, 2025
SOUTHBOROUGH, MA, UNITED STATES, June 20, 2025 /EINPresswire.com/ -- Epiphany Massachusetts Drug …
Structure Therapeutics Announces Two Late-Breaking Poster Presentations at the American Diabetes Association 85th Scientific Sessions Including New Preclinical Data for Oral Small Molecule Amylin Agonist, ACCG-2671
GlobeNewswire
·
June 20, 2025
SAN FRANCISCO, June 20, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, today announced two upcoming late- …
Salt Cave Builder Warns: Misleading Price Claims Are Hurting the Salt Therapy Industry
EIN Presswire
·
June 20, 2025
Industry Pioneer Dr. Margaret Smiechowski Exposes the Risks of Cheap Salt Rooms ORLEANS, MA, UNITED STATES, June 20, 2025 /EINPresswire.com/ -- As salt therapy continues to grow in popularity across the United States, misinformation about the cost and …
Inozyme Pharma, Inc. Announces Postponement of 2025 Annual Meeting of Stockholders
GlobeNewswire
·
June 20, 2025
BOSTON, June 20, 2025 (GLOBE NEWSWIRE) -- Inozyme Pharma, Inc. (Nasdaq: INZY) today announced that it has postponed its 2025 Annual Meeting of Stockholders (the “Annual Meeting”), which was scheduled to be held on June 25, 2025, in light of the previously …
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 20, 2025
NOVATO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of …
Cyclacel Pharmaceuticals Announces $3 Million Private Placement Offering of Convertible Preferred Stock
GlobeNewswire
·
June 20, 2025
KUALA LUMPUR, June 20, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (“Cyclacel”) (NASDAQ: CYCC, NASDAQ: CYCCP), a biopharmaceutical company that develops innovative cancer medicine, today announced that it has entered into a securities purchase …
The Ensign Group, Inc. Announces Retirement of Its Executive Chairman
GlobeNewswire
·
June 20, 2025
SAN JUAN CAPISTRANO, Calif., June 20, 2025 (GLOBE NEWSWIRE) -- The Ensign Group, Inc. (Nasdaq: ENSG or “Ensign”), the parent company of the Ensign™ group of companies, which invest in and provide skilled nursing and senior living services, physical, …
AIM ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements
GlobeNewswire
·
June 20, 2025
NYSE American previously issued similar warning for same matter and issued the new notice because the deficiency remains as of March 31, 2025 AIM has until June 11, 2026 to regain compliance OCALA, Fla., June 20, 2025 (GLOBE NEWSWIRE) -- AIM ImmunoTech Inc …
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
June 20, 2025
WALTHAM, Mass., June 20, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader in the development and commercialization of therapies for …
ArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLC
GlobeNewswire
·
June 20, 2025
NEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced …
Larimar Therapeutics Announces Regulatory Update Call on the Nomlabofusp Program for the Treatment of Friedreich’s Ataxia
GlobeNewswire
·
June 20, 2025
BALA CYNWYD, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the Company will host a …
Wave Life Sciences Announces Oral Presentation of Preclinical Data Supporting WVE-007’s Mechanism (INHBE) to Reduce Fat, Preserve Muscle, and Induce Healthy Weight Loss at ADA's Annual Scientific Sessions
GlobeNewswire
·
June 20, 2025
Presentation to highlight WVE-007 (INHBE GalNAc-siRNA) as a potential novel and unique obesity treatment leading to healthy weight loss and supporting preclinical data demonstrating potent and durable reduction in Activin E resulting in fat loss with …
PharmAla Files Preliminary Base Shelf Prospectus
GlobeNewswire
·
June 20, 2025
TORONTO, June 20, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its …
Shuttle Pharmaceuticals Announces Pricing of $4.25 Million Private Placement Priced At-the-Market
GlobeNewswire
·
June 20, 2025
GAITHERSBURG, Md., June 20, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer …
Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market
GlobeNewswire
·
June 20, 2025
PITTSBURGH, June 20, 2025 (GLOBE NEWSWIRE) -- Lipella Pharmaceuticals Inc. (OTC: LIPO) (“Lipella” or the “Company”), a clinical-stage biotechnology company focused on developing therapies for diseases with significant unmet needs, today announced that the …
SlimJaro Advanced Weight Loss Supplement in 2025: Can Targeting Inflammation Extra Body Fat, Read Slim Jaro Benefits & Side Effects
GlobeNewswire
·
June 20, 2025
New York City, NY, June 20, 2025 (GLOBE NEWSWIRE) -- In 2025, weight loss has become more complicated than simply cutting calories or hitting the gym. Many people around the world are following standard health advice yet still struggle with slow or …
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules
GlobeNewswire
·
June 20, 2025
OSE Immunotherapeutics Reaffirms Commitment to Holding a Transparent and Serene General Meeting in Compliance with Market Rules Nantes, June 20th, 2025, 7:30 p.m. - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), publishes a “Questions and …
OSE Immunotherapeutics réaffirme son engagement à tenir une Assemblée Générale dans la transparence, la sérénité des débats, et le respect des règles de marché
GlobeNewswire
·
June 20, 2025
OSE Immunotherapeutics réaffirme son engagement à tenir une Assemblée Générale dans la transparence, la sérénité des débats, et le respect des règles de marché NANTES, France, 20 juin 2025, 19 heures 30 – OSE Immunotherapeutics SA (ISIN: FR0012127173; …
GH Research Submits Complete IND Hold Response to FDA Ahead of Schedule
GlobeNewswire
·
June 20, 2025
DUBLIN, June 20, 2025 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced that, in June, …